BMJ Visual Summary

FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway

By Elisabeth Mahase Taken Directly from the BMJ doi: https://doi.org/10.1136/bmj.n1898 Criticisms of the US Food and Drug Administration’s accelerated approval process have resurfaced after the recent…

View More FDA allows drugs without proven clinical benefit to languish for years on accelerated pathway
ECG

Sodium-glucose co-transporter 2 inhibitors – new frontier in the treatment of heart failure

By Syed Ghias Take Home Messages Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a novel class of oral hypoglycaemic medications which have been shown to be effective…

View More Sodium-glucose co-transporter 2 inhibitors – new frontier in the treatment of heart failure
Image of a heart with myocardial infarction

Prasugrel and ticagrelor associated with similar efficacy and safety following myocardial infarction

By Ahmed El-Medany In a large retrospective study by Venetsanos et al, researchers analysed 37,990 patients from the SWEDEHEART registry with myocardial infarction (MI) who…

View More Prasugrel and ticagrelor associated with similar efficacy and safety following myocardial infarction